查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553475

骨髓发育不良症候群药物市场规模、份额和趋势分析报告：2024-2030 年按治疗、给药途径、最终用途、地区和细分市场进行的预测

Myelodysplastic Syndrome Drugs Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immune Treatments), By Route Of Administration, By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

骨髓发育不良症候群药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，2030年全球骨髓发育不良症候群药物市场规模预计将达到52.8亿美元，2024年至2030年复合年增长率为9.1%。

强大的产品平臺、不断增加的老年人口以及有利的政府措施等因素正在推动市场发展。

MDS 是由控制血球发育的一个或多个基因突变引起的。患有这种疾病的患者表现出血小板减少、嗜中性白血球低下和贫血等临床症状。儘管大多数病例（超过 90%）发生在 60 岁以上的人群中，但这种疾病可以发生在任何年龄，并且男性比女性更常见。约 30% 的 MDS 病例会进展为急性骨髓性白血病(AML)。

由于来那Revlimid)的强劲销售，免疫调节剂领域预计将保持其在 MDS 治疗市场的主导地位。在 Luspatercept 和 Aranesp 可能核准的推动下，恶性物领域预计将比低甲基化药物获得更高的市场占有率，并对整体市场扩张做出重大贡献。

由于MDS在分子层面上是一种高度异质性的疾病，因此开发治疗罕见患者亚群的新药是一个重要的挑战。此外，由于标准治疗模式无效而导致的发病问题和生活品质下降也给老年人带来不便。

骨髓发育不良症候群药物市场报告亮点

  • 干细胞移植将主导市场，2023年将占38.7%的份额。干细胞移植使用健康捐赠者的干细胞来取代受损的骨髓。干细胞移植可以恢復因高剂量化疗或放射线治疗受损的骨髓。
  • 2023年，口服给药途径占最大的市场收益占有率，达59.5%。口服药物的优势，例如消除与锭剂和注射相关的不利事件，是推动市场成长的一些因素。
  • 2023 年，医院产业占据最大的市场收益占有率，达到 48.6%。慢性病盛行率的上升促使医院提供无法家用治疗的加护治疗。
  • 2023年北美骨髓发育不良症候群药物市场收益占有率占比为35.44%。这一增长是由老年人口的增加和骨髓发育不良症候群（MDS）的增加所推动的。
  • 据估计，亚太地区骨髓发育不良症候群药物市场在预测期内复合年增长率最快。这一增长背后的主要因素是人口老化的加剧以及企业和研究机构的进步。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章骨髓发育不良症候群药物市场变数、趋势、范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 骨髓发育不良症候群药物市场分析工具
    • 波特的分析
    • PESTEL分析

第四章骨髓发育不良症候群药物市场：依治疗方法估算与趋势分析

  • 细分仪表板
  • 骨髓发育不良症候群药物市场：2023 年和 2030 年治疗的变异分析
  • 化疗
  • 免疫疗法
  • 干细胞移植
  • 其他治疗类型

第五章骨髓发育不良症候群药物市场：按应用估计和趋势分析

  • 细分仪表板
  • 骨髓发育不良症候群药物市场：2023 年及 2030 年给药途径变异分析
  • 口服
  • 胃肠外的

第六章骨髓发育不良症候群药物市场：最终用途的估计和趋势分析

  • 细分仪表板
  • 骨髓发育不良症候群药物市场：2023 年和 2030 年最终用途变异分析
  • 医院
  • 诊所
  • 其他的

第七章骨髓发育不良症候群药物市场：区域估计和趋势分析

  • 2023 年及 2030 年骨髓发育不良症候群药物市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
  • 拉丁美洲
    • 巴西
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Celgene Corporation
    • Otsuka Pharmaceutical Co. Ltd
    • Amgen Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Limited
    • Takeda Pharmaceutical Company Ltd
    • Mylan NV
    • Cipla Pharmaceutical Limited
    • Onconova Therapeutics
    • Hikma Pharmaceuticals PLC
简介目录
Product Code: GVR-2-68038-434-5

Myelodysplastic Syndrome Drugs Market Growth & Trends:

The global myelodysplastic syndrome drugs market size is expected to reach USD 5.28 billion by 2030, exhibiting at a CAGR of 9.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. Factors such as strong product pipeline, rising geriatric population, and favorable government initiatives are driving the market.

MDS is caused by mutation of one or more genes that control development of blood cells. Patients with this condition may present with clinical manifestations such as thrombocytopenia, neutropenia, and anemia. Although majority of cases (over 90%) are reported in people over the age of 60, the condition can occur at any age, more frequently in men than in women. About 30% of MDS cases advance to acute myeloid leukemia (AML).

The immunomodulatory drug segment is expected to retain its dominant position in the MDS drugs market due to strong sales of Revlimid. Supported by potential approvals of luspatercept and Aranesp, the anti-anemics drug segment is forecast to gain higher market share than hypomethylating agents, thus contributing significantly to the overall expansion of the market.

Developing novel drugs for the treatment of rare subsets of MDS patients is a key challenge as the disease is highly heterogeneous at the molecular level. In addition, morbidity issues and poor quality of life due to incapacitating effects of the standard of care treatment paradigms are causes of inconvenience for geriatric population.

Myelodysplastic Syndrome Drugs Market Report Highlights:

  • Stem cell transplant dominated the market and accounted for a share of 38.7% in 2023. Stem transplants use stem cells from healthy donors to replace damaged bone marrow. Stem cell transplant has the potential to restore the bone marrow damaged from high chemotherapy doses or from radiation therapy.
  • Oral route of administration accounted for the largest market revenue share of 59.5% in 2023. The advantages of oral medicines, such as tablets and the elimination of injection-associated adverse events, are a few factors driving the market growth.
  • The hospital segment accounted for the largest market revenue share of 48.6% in 2023. The rising prevalence of chronic diseases is driving hospitals to provide a concentrated treatment that cannot be treated at home.
  • North America's myelodysplastic syndromes drugs market dominated with revenue share of 35.44% in 2023. This growth is attributed to the growing geriatric population and growing incidences of myelodysplastic syndrome (MDS).
  • The Asia Pacific myelodysplastic syndrome drugs market is estimated to register the fastest CAGR over the forecast period. The growth is primarily attributed to the rising geriatric population and advancements by companies and research institutions.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Myelodysplastic Syndrome Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Myelodysplastic Syndrome Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Myelodysplastic Syndrome Drugs Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Myelodysplastic Syndrome Drugs Market: Product Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Chemotherapy
    • 4.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Immune Treatments
    • 4.4.1. Immune Treatments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Stem Cell Transplant
    • 4.5.1. Stem Cell Transplant Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Other Treatment Types
    • 4.6.1. Other Treatment Types Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Myelodysplastic Syndrome Drugs Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Myelodysplastic Syndrome Drugs Market: Route of Administration Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Oral
    • 5.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Parenteral
    • 5.4.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Myelodysplastic Syndrome Drugs Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Myelodysplastic Syndrome Drugs Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Clinics
    • 6.4.1. Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Other
    • 6.5.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Myelodysplastic Syndrome Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Myelodysplastic Syndrome Drugs Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Myelodysplastic Syndrome Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Celgene Corporation
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Otsuka Pharmaceutical Co. Ltd
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Amgen Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Teva Pharmaceutical Industries Ltd.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Sun Pharmaceutical Industries Limited
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Takeda Pharmaceutical Company Ltd
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Mylan N.V.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Cipla Pharmaceutical Limited
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Onconova Therapeutics
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Hikma Pharmaceuticals PLC
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives